<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879358</url>
  </required_header>
  <id_info>
    <org_study_id>SORT OUT VII</org_study_id>
    <secondary_id>OUH</secondary_id>
    <nct_id>NCT01879358</nct_id>
  </id_info>
  <brief_title>Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent</brief_title>
  <acronym>SORT OUT VII</acronym>
  <official_title>Randomized Comparison of a Sirolimus Eluting ORSIRO Stent With a Biolimus-eluting NOBORI Stent in Patients Treated With Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <authority>Denmark: The Danish National Committee on Biomedical Research Ethics</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is
      to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the
      biolimus-eluting NOBORI stent in a population-based setting, using registry detection of
      clinically driven events
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SORT OUT VII is a randomized, multicenter, all-comer, two-arm, non-inferiority trial
      comparing the sirolimus eluting ORSIRO stent to the biolimus-eluting NOBORI stent in
      treating atherosclerotic coronary artery lesions.

      Primary Endpoint:

      Target lesion failure within 12 months of stent implantation (combination of  cardiac death,
      myocardial infarction (not index procedure related) not related to other than index lesion
      or target lesion revascularization).

      Secondary Endpoints:

      Individual components of the primary end point comprised the secondary end points and stent
      thrombosis rate according to the Academic Research Consortium definition (see protocol for
      further specification of secondary endpoints).

      Clinically driven event detection will be used to avoid study-induced reinterventions. Data
      on mortality, hospital admission, coronary angiography, repeat percutaneous coronary
      intervention, and coronary bypass surgery will be obtained for all randomly allocated
      patients from the following national Danish administrative and healthcare registries: the
      Civil Registration System; the Western Denmark Heart Registry; the Danish National Registry
      of Patients, which maintains records on all hospitalizations in Denmark; and the Danish
      Registry of Causes of Death

      Inclusion criteria:

      at least 18 years old chronic stable coronary artery disease or acute coronary syndromes at
      least one coronary artery lesion with more than 50% diameter stenosis requiring treatment
      with a drug-eluting stent

      Exclusion criteria:

      life expectancy of less than one year allergy to aspirin, clopidogrel, sirolimus, or
      biolimus participation in another randomized trial nability to provide written informed
      consent
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cardiac death, myocardial infarction or target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Target lesion failure within 12 months of stent implantation (combination of  cardiac death, myocardial infarction (not index procedure related) not related to other than index lesion or target lesion revascularization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death, myocardial infarction, target lesion revascularization, target vessel revascularization, all cause mortality, stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiac mortality Myocardial infarction Target lesion revascularization Target vessel revascularization All cause mortality Stent thrombosis rate according to the Academic Research Consortium definition Secondary endpoints will be assessed after 1 year, 2 years, 3 years, 4 years and 5 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2314</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>ORSIRO stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ORSIRO stent group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOBORI stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NOBORI stent group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting stent</intervention_name>
    <arm_group_label>ORSIRO stent</arm_group_label>
    <arm_group_label>NOBORI stent</arm_group_label>
    <other_name>ORSIRO sirolimus-eluting stent</other_name>
    <other_name>NOBORI biolimus-eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or over with chronic stable coronary artery disease or acute
             coronary syndromes, and at least one coronary artery lesion with more than 50%
             diameter stenosis, requiring treatment with a drug-eluting stent. There are no
             restrictions on number of treated lesions, number of treated vessels, or lesion
             length.

        Exclusion Criteria:

          -  Exclusion criteria are life expectancy of less than one year; an allergy to aspirin,
             clopidogrel, ticagrelor, prasugral, sirolimus, or biolimus; participation in another
             randomized trial; or inability to provide written informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens F Lassen, MD DMSci</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisette Okkels Jensen, MD DMSci PhD</last_name>
    <phone>004565412620</phone>
    <email>okkels@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Thayssen, MD DMSci</last_name>
    <phone>004565412681</phone>
    <email>per.thayssen@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisette Okkels Jensen, MD DMSci PhD</last_name>
      <phone>004565412620</phone>
      <email>okkels@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Per Thayssen, MD DMSci</last_name>
      <phone>004565412691</phone>
      <email>per.thayssen@ouh.regionsyddanmark.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Lisette Okkels Jensen, MD DMSci PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22308301</url>
    <description>SORT OUT IV with same clinically event driven methodology</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 14, 2013</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Lisette Okkels Jensen</investigator_full_name>
    <investigator_title>MD DMSci PhD</investigator_title>
  </responsible_party>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
